CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

Sss Co

Sss Co is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cassini Technologies

Driven by curiosity and love of science Cassini has been dedicated to push the boundaries of corneal diagnostics solutions ✓ Advised by top surgeons

Spinal Elements

Spinal Elements, Inc. is an innovative spine technology company that delivers new standards in spine surgery. Spinal Elements, previously Amendia.

Revive Therapeutics

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.